about
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the LiteratureManaging Side Effects of Vemurafenib Therapy for Advanced MelanomaAvoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib.No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Dermatological toxicity associated with targeted therapies in cancer: optimal management.Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations.Management of Dermatologic Complications of Lung Cancer Therapies.Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation.Late-onset robust curly hair growth in a patient with BRAF-mutated metastatic melanoma responding to dabrafenib.Profile of vemurafenib-induced severe skin toxicities.Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Transient MEK inhibitor-associated retinopathy in metastatic melanoma.Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation.[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions
P2860
Q26752774-721CB5B4-82E4-4084-A602-89889CD8281EQ26795510-7812B706-DB38-4F2D-A637-2C6CF8B89DCFQ28079359-A0FEC9F9-E892-4A98-987B-4D10EA9EBE6BQ34403517-513558D2-42E0-4E88-8FE3-F308277CF033Q35013602-C2630DCA-151E-46C3-84F9-3FF67A9E4FB4Q35381501-21696633-AC34-4DF6-9311-C3F8DED18050Q37697778-B01A4621-3B83-4D6F-87A2-22D3D410C98DQ38139282-2DA43B42-662A-4CD0-BBA8-DDB07AF42639Q38203019-0944C567-70B7-44AB-86AE-C7891AE0CCFBQ38239381-4D022882-214D-4D80-B93B-93ED7BB10686Q38555837-F40E6CB1-BA37-498E-A1B9-151E7C7DB905Q38580488-C472D328-2373-4D28-B3C5-5D1BBF0ACB7BQ38867037-09C92AE1-58AD-4B70-BEB2-21E9FFAB8EAAQ38899353-D23E1A63-A40A-4A40-8131-B4870861EDC0Q40366752-F2FC3E5D-64CE-471C-853B-7E8550B8EF0CQ46721978-E0F653C9-7525-4623-B5CF-2FD0D160CEE3Q50455744-A106FBB3-6022-4758-9D56-EA87146EEA88Q50954724-A63E81C9-050F-4D68-B208-B65392E507B3Q53063698-280C805A-1A84-459B-880F-7DCA63D05AFBQ54263364-12B9340A-AF0C-494E-8EE2-AEAF78278615Q54325214-1FF5CC78-C634-445C-BC43-B2264ED381C3Q54378191-59080BB7-AC5D-4364-82BB-98C604EBB2EBQ58781631-A3A82CFA-F2F3-451A-9B9F-02909068BAB3
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
RASopathic skin eruptions during vemurafenib therapy
@ast
RASopathic skin eruptions during vemurafenib therapy
@en
RASopathic skin eruptions during vemurafenib therapy
@nl
type
label
RASopathic skin eruptions during vemurafenib therapy
@ast
RASopathic skin eruptions during vemurafenib therapy
@en
RASopathic skin eruptions during vemurafenib therapy
@nl
prefLabel
RASopathic skin eruptions during vemurafenib therapy
@ast
RASopathic skin eruptions during vemurafenib therapy
@en
RASopathic skin eruptions during vemurafenib therapy
@nl
P2093
P2860
P1433
P1476
RASopathic skin eruptions during vemurafenib therapy
@en
P2093
Benedetta Belloni
Jeannine D Rinderknecht
Jivko Kamarashev
Katrin Kerl
Sima Rozati
Simone M Goldinger
P2860
P304
P356
10.1371/JOURNAL.PONE.0058721
P407
P577
2013-01-01T00:00:00Z